Thymosin Alpha-1: Research Applications Comparison
Choosing thymosin alpha-1 for cancer adjunct research requires aligning peptide specifications with study design. Different applications demand different purity thresholds, sequencing verification levels, and storage formats. Dendritic cell maturation assays (
This comparison does not assign a generated winner or score.
- Choosing thymosin alpha-1 for cancer adjunct research requires aligning peptide specifications with study design. Different applications demand different purity thresholds, sequencing verification levels, and storage formats.
- Dendritic cell maturation assays (in vitro)
- ≥95% by HPLC
- Mass spec confirmation (3,108 Da)
- 10–100 μg/mL culture media
- Lyophilised, single-use aliquots
- Lower purity acceptable for screening; sequencing not critical if mass is confirmed
- T-cell proliferation assays (in vitro)
- ≥98% by HPLC
- N-terminal sequencing (10 residues)
- 1–10 μg/mL culture media
- Lyophilised, reconstitute fresh per experiment
- Sequence verification required. Deletion peptides produce false negatives
- Tumor microenvironment studies (in vivo, mouse models)
- Full sequencing (28 residues) or MS/MS
- 100–200 μg per injection, twice weekly
- Lyophilised, sterile-filtered post-reconstitution
- Full sequencing mandatory for publication; endotoxin testing required (<1 EU/mg)
- Checkpoint inhibitor combination trials (preclinical)
- ≥99% by HPLC
- Full sequencing + endotoxin testing
- 1.6 mg human equivalent dose
- Lyophilised, GMP-grade synthesis preferred
- Highest purity required; regulatory-grade CoA needed for IND submissions
- Post-chemotherapy immune recovery models
- 100–200 μg per injection
- Lyophilised, stored at −20°C until use
- Sequencing verifies immune-active region; batch consistency critical across multi-week studies
- Cytokine secretion profiling (multiplex assays)
- Mass spec + sequencing
- 0.1–10 μg/mL
- Lyophilised, single-use vials
- Off-target cytokine activation from impurities confounds results. High purity non-negotiable